FAQ/Help |
Calendar |
Search |
Today's Posts |
|
![]() |
#1 | |||
|
||||
Elder
|
Quote:
They will make BILLIONS of $$$ off of us this year, whether its an injectable or a pill or a cream or an IV infusion. They WILL be allowed to get away with it, and those with great insurance will get it, and some without insurance will get a limited supply and many will simply go without. They are NOT interested in curing or halting MS, they ARE interested in making money off of it. Sad, just sad.
__________________
RRMS 3/26/07 . Betaseron 5/18/07 . Elevated LFTs Beta DC 7/07 Copaxone 8/7/07 . . |
|||
![]() |
![]() |
![]() |
#2 | |||
|
||||
Grand Magnate
|
I don't necessarily think it is sad. Research costs money, lots of money. Just think of the years it took to produce this one particular drug and the trials it went through. That being said, I don't know that the 4000.00 per month price tag can be justified.
|
|||
![]() |
![]() |
Reply |
|
|
![]() |
||||
Thread | Forum | |||
What I learned about fingolimod today | Multiple Sclerosis | |||
new information on Gilenia (Fingolimod) | Multiple Sclerosis | |||
Novartis had changed the name of Fingolimod to Gilenia (aka FTY720). | Multiple Sclerosis | |||
FTY720/Fingolimod | Multiple Sclerosis | |||
Fingolimod/FTY720 Research from ECTRIMS | Multiple Sclerosis |